News >

TAS-102 Effective in Gastric/GEJ Cancer, Regardless of Prior Gastrectomy

OncLive Staff
Published: Monday, Oct 14, 2019

David H. Ilson, MD, PhD, attending physician and professor of medicine at Memorial Sloan Kettering Cancer Center

David H. Ilson, MD, PhD

Patients with metastatic gastric/gastroesophageal junction (GEJ) cancer had improved overall survival (OS) with TAS-102 (trifluridine/tipiracil; FTD/TPI; Lonsurf), irrespective of prior gastrectomy, according to a preplanned subgroup analysis from the phase III TAGS trial published in JAMA Oncology.1,2



  1. Analysis of patients with prior gastrectomy treated with LONSURF® (trifluridine and tipiracil) published in JAMA Oncology. Published October 14, 2019. Accessed October 14, 2019.
  2. Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial [published online October 14, 2019]. JAMA Oncol. 2019. doi: 10.1001/jamaoncol.2019.3531.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication